Deflazacort and Tenosynovitis - a phase IV clinical study of FDA data

Summary:

Tenosynovitis is reported as a side effect among people who take Deflazacort (deflazacort), especially for people who are female, 60+ old, also take Dilaudid, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Tenosynovitis when taking Deflazacort. It is created by eHealthMe based on reports of 1,456 people who have side effects when taking Deflazacort from the FDA, and is updated regularly.

What is Deflazacort?

Deflazacort has active ingredients of deflazacort. eHealthMe is studying from 1,457 Deflazacort users. Check the latest studies of Deflazacort.

What is Tenosynovitis?

Tenosynovitis (inflammation of the fluid-filled sheath (called the synovium) that surrounds a tendon) is found to be associated with 457 drugs and 490 conditions by eHealthMe. Check the latest studies of Tenosynovitis.

On Jul, 12, 2026

1,456 people reported to have side effects when taking Deflazacort.
Among them, 28 people (1.92%) have Tenosynovitis.

Among these 28 people:

What is the gender of people who have Tenosynovitis when taking Deflazacort? *

female: 100 %
male: 0.0 %

What is the age of people who have Tenosynovitis when taking Deflazacort? *

What are other drugs people take besides Deflazacort? *

What are other side effects people have besides Tenosynovitis? *

Acute Kidney Failure: 28 people, 100.00%
Bronchiectasis (abnormal widening of the bronchi or their branches, causing a risk of infection): 28 people, 100.00%
Localised Infection (infection at the single location): 28 people, 100.00%
Osteoporosis (bones weak and more likely to break): 28 people, 100.00%
Bursitis Infective (the bursa can become infected, this is called infected bursitis): 28 people, 100.00%
Peripheral Vascular Disorder: 28 people, 100.00%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 28 people, 100.00%
Pneumonia: 28 people, 100.00%
Staphylococcal Infection (an infection with staphylococcus bacteria): 28 people, 100.00%
Skin Ulcer: 28 people, 100.00%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 28 people, 100.00%
Pain: 5 people, 17.86%
Diabetes: 5 people, 17.86%
Abdominal Pain Upper: 4 people, 14.29%
Juvenile Rheumatoid Arthritis (joint inflammation in children due to systemic disease): 1 person, 3.57%

* Approximation only. Some reports may have incomplete information.

Do you take Deflazacort and have Tenosynovitis?

- Check whether Tenosynovitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Deflazacort:

Deflazacort (1,457 reports)

Tenosynovitis treatments and more:

Tenosynovitis (4,673 reports)

Browse all side effects of Deflazacort:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Tenosynovitis:

Tenosynovitis (457 drugs)

Browse all the conditions that are associated with Tenosynovitis:

Tenosynovitis (490 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on deflazacort (the active ingredients of Deflazacort) and Deflazacort (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.